Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.5glegtPn.js ...

The deal will give Zimmer Biomet access to Paragon's surgical implants and equipment used to treat foot and ankle ailments, ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.4, a ...

Fintel reports that on January 29, 2025, Needham downgraded their outlook for Paragon 28 (NYSE:FNA) from Buy to Hold. Analyst ...

Fintel reports that on January 29, 2025, Canaccord Genuity downgraded their outlook for Paragon 28 (NYSE:FNA) from Buy to Hold. Analyst Price Forecast Suggests 12.55% Upside As of January 29, 2025, ...

Paragon 28, Inc. (NYSE:FNA) shares are trading higher premarket on Wednesday. On Tuesday, the company inked a deal to be ...

Stephens downgraded Paragon 28 (FNA) to Equal Weight from Overweight with a $13 price target after Zimmer Biomet (ZBH) agreed to acquire the ...

NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business, with a $1.1 billion deal to acquire the ...

Zimmer Biomet made a major play in the foot and ankle treatment space today, announcing it will spend $1.2 billion to acquire ...

Paragon 28 shares rose 8.4% after Zimmer Biomet Holdings agreed to acquire the company. Shares were trading around $13.02. The stock is up about 2.6% over the last year.